Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Gilles Crochet,Gloria Iacoboni, Audrey Couturier,Emmanuel Bachy, Josu Iraola-Truchuelo,Thomas Gastinne, Guillaume Cartron, Tom Fradon, Bastien Lesne,Mi Kwon,Romain Gounot,Nuria Martinez-Cibrian,Cristina Castilla-Llorente, Pau Abrisqueta,Manuel Guerreiro,Clementine Sarkozy, Jose Aspa-Cilleruelo, Vincent Camus,Stéphanie Guidez,Adrien Chauchet

Blood（2024）

引用 0|浏览3

暂无评分

摘要

In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要